- AstraZeneca said it had agreed to buy a US Food and Drug Administration priority review voucher for $95m in cash from a subsidiary of Swedish Orphan Biovitrum.

The voucher would give the company access to FDA priority review of a single new drug application or biologics license application, reducing the target review time and may potentially lead to an expedited approval.

The transaction remained subject to clearance under the Hart-Scott Rodino (HSR) Antitrust Improvements Act, the company said.

Story provided by